Publications

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. by Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 257-260

In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (1): 49-53

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. by Biedenbach DJ, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 245-250

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 40 (4): 173-177

Assessment of BMS284756 MIC and 5-µg disk diffusion quality control studies tested against seven American type culture collection strains. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 225-228

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. by Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ and Jones RN published in Antimicrob. Agents Chemother. 2000; 44 (10): 2883-2886

Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility. by Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP and Seifert H published in Clin. Infect. Dis. 2000; 31 (3): 690-697

Russian Klebsiella pneumoniae isolates that express extended-spectrum β-lactamases. by Winokur PL, Eidelstain MV, Stetsiouk O, Stratchounski L, Blahova J, Reshedko GK, Croco MA, Hollis RJ, Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2000; 6 (2): 103-108

Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: Results from SENTRY Antimicrobial Surveillance Program (1997-98). by Sader HS, Gales AC, Granacher TD, Pfaller MA and Jones RN published in Braz. J. Infect. Dis. 2000; 4 (5): 245-254

Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. by Ramphal R, Hoban DJ, Pfaller MA, Jones RN. published in Diagn. Microbiol. Infect. Dis. 2000; 36 (2): 125-129

Pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae in a respiratory chemoprophylaxis intervention study using azithromycin. by Putnam SD, Gray GC, Biedenbach DJ and Jones RN published in Clin. Microbiol. Infect. 2000; 6 (1): 2-8

Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. by Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S and Hollis RJ published in Antimicrob. Agents Chemother. 2000; 44 (3): 747-751

Evaluation of the discriminatory powers of the Dienes test and ribotyping as typing methods for Proteus mirabilis. by Pfaller MA, Mujeeb I, Hollis RJ, Jones RN and Doern GV published in J. Clin. Microbiol. 2000; 38 (3): 1077-1080

Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. by Pfaller MA, Messer SA, Houston A, Mills K, Bolmstrom A and Jones RN published in J. Clin. Microbiol. 2000; 38 (10): 3715-3717

Global trends in an antimicrobial resistance surveillance system: Results from the MYSTIC Programme. by Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2000; 6 (Suppl 1): 74

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). by Pfaller MA and Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 25-37

Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications. by Odland BA, Erwin ME and Jones RN published in J. Clin. Microbiol. 2000; 38 (1): 453-455

Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent. Quality Control Study Group. by Marshall SA, Erwin ME, and Jones RN published in J. Clin. Microbiol. 2000; 38 (6): 2462-2463

Evaluation of quinupristin/dalfopristin (Synercid) and RPR 106972 stability in susceptibility testing media. by Marshall SA, Kugler KC, and Jones RN published in Int. J. Antimicrob. Agents 2000; 15 (4): 291-297

Activity of macrolides, lincosamines, streptogramins and fluoroquinolones against Streptococcus pneumoniae and enterococci isolates from the western hemisphere: Example of international surveillance (SENTRY Antimicrobial Surveillance Program )in the development of new drugs. by Lewis MT and Jones RN published in Braz. J. Infect. Dis. 2000; 4 (1): 15-21

Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection. by Lewis RE, Klepser ME, Ernst EJ, Snabes MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (1): 51-55

Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (1998). by Lewis MT, Gales AC, Sader HS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (1): 63-74

Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): Case reports from the SENTRY Antimicrobial Surveillance Program. by Kugler KC, Denys GA, Wilson ML, and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (4): 269-272

Anti-gonococcal activity of gemifloxacin against fluoroquinolone- resistant strains and a comparison of agar dilution and Etest methods. by Jones RN, Deshpande LM, Erwin ME, Barrett MS and Beach ML published in J. Antimicrob. Chemother. 2000; 45 (Suppl 1): 67-70

In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997- 1998. by Jones RN, Jenkins SG, Hoban DJ, Pfaller MA and Ramphal R published in Int. J. Antimicrob. Agents. 2000; 15 (2): 111-118

In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. by Jones RN, Jenkins SG, Hoban DJ, Pfaller MA and Ramphal R published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 93-98

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). by Jones RN, Croco MA, Kugler KC, Pfaller MA and Beach ML published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 115-125

Cefditoren activity against nearly 1,000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. by Jones RN, Biedenbach DJ and Johnson DM published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 143-146

Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group. by Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 2000; 37 (3): 195-201

Evaluation of gemifloxacin (SB-265805, LB20304a): In vitro activity against over 6,000 Gram-positive pathogens from diverse geographic areas. by Jones RN, Pfaller MA and Erwin ME published in Int. J. Antimicrob. Agents 2000; 15 (3): 227-230

Perspectives on the development of new antimicrobial agents for resistant Gram-positive pathogens. by Jones RN published in Braz. J. Infect. Dis. 2000; 4 (1): 1-8

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY Antimicrobial Surveillance Program. by Jones RN and Pfaller MA. published in Clin. Infect. Dis. 2000; 31 (Suppl 2): S16-23

Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. by Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 1-8

Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: Significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). by Jones RN and Pfaller MA published in J. Clin. Microbiol. 2000; 38 (11): 4298-4299

Potencies of newer fluoroquinolones against viridans group streptococci isolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): Beyond Canada! by Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2000; 44 (10): 2922-2923

Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. by Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 99-105

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: Report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). by Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, Pfaller MA and Doern GV published in J. Antimicrob. Chemother. 2000; 45 (3): 295-303

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 1997-98. SENTRY Study Group. by Gales AC, Jones RN, Pfaller MA, Gordon KA and Sader HS published in Int. J. Infect. Dis. 2000; 4 (2): 75-84

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. by Gales AC and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (1): 19-36

Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. by Gales AC, Gordon KA, Wilke WW, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (1): 61-64

Oxazolidinones: A review. by Diekema DI and Jones RN published in Drugs 2000; 59 (1): 7-16

Microbiology of infections in the coronary care unit. by Diekema DJ and Jones RN published in Antibiotics for Clinicians2000; 4 (Suppl 1): 5-10

Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. by Diekema DJ, Pfaller MA, Jones RN, Doern GV, Kugler KC, Beach ML and Sader HS published in Int. J. Antimicrob. Agents 2000; 13 (4): 257-271

Genetic relatedness of multidrug-resistant, methicillin (oxacillin)- resistant Staphylococcus aureus bloodstream isolates from SENTRY Antimicrobial Resistance Surveillance centers worldwide, 1998. by Diekema DJ, Pfaller MA, Turnidge J, Verhoef J, Bell J, Fluit AC, Doern GV and Jones RN published in Microb. Drug Resist. 2000; 6 (3): 213-221

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2,000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999). by Deshpande LM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 139-142

In vitro activity of ceftiofur tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum β-lactamase producing strains. by Deshpande L, Pfaller MA and Jones RN published in Int. J. Antimicrob. Agents 2000; 15 (4): 271-275

Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. by Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, Marshall SA and Jones RN published in J. Clin. Microbiol. 2000; 38 (5): 1818-1822

Fluoroquinolone-resistant Haemophilus influenzae: Frequency of occurrence and analysis of confirmed strains in the SENTRY Antimicrobial Surveillance Program (North and Latin America). by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (4): 255-259

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. by Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ and Ballow CH published in Diagn. Microbiol. Infect. Dis. 2000; 36 (3): 145-158

Group B streptococci causing neonatal bloodstream infection: Antimicrobial susceptibility and serotyping results from SENTRY centers in the western hemisphere. by Andrews JI, Diekema DJ, Hunter SK, Rhomberg PR, Pfaller MA, Jones RN and Doern GV published in Am. J. Obstet. Gynecol. 2000; 183 (4): 859-862